GEDAD Beteiligungs- und Verwaltungs-GmbH

GEDAD Beteiligungs- und Verwaltungs‑GmbH holds and manages corporate investments and is the parent company of a group that, particularly through Cellex Cell Professionals GmbH, provides full‑service offerings to pharmaceutical companies, biotech firms, clinics and research institutions in the field of cellular therapies. The group performs manufacturing of genetically modified cells (including CAR‑T cell therapeutics), transport/logistics and cryopreservation and operates GMP facilities in Cologne (Ossendorf and Deutz). Other business activities include cell collection/donations and bone marrow collections; in 2023 the group reported consolidated revenues of TEUR 43,402, of which TEUR 33,093 related to the manufacturing of genetically modified cells and TEUR 10,190 to cell collection/donations. The company also holds stakes in startups (including 28.33 % in AvenCell Therapeutics Inc.), employed on average 260 people in the year and reported consolidated equity of TEUR 36,435 and an equity ratio of 76 % as of 31 Dec 2023. GEDAD Beteiligungs- und Verwaltungs-GmbH is a family business with open business succession.